A5005503232- Treatment of Major Depression
- Functional Brain Connectivity Studies
- Neurological disorders and treatments
- Tryptophan and brain disorders
- Mental Health Research Topics
- Schizophrenia research and treatment
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Advanced MRI Techniques and Applications
- Transcranial Magnetic Stimulation Studies
- Personality Disorders and Psychopathology
- Psychological Treatments and Disorders
- Neurotransmitter Receptor Influence on Behavior
- Stress Responses and Cortisol
- Advanced Neuroimaging Techniques and Applications
- Bipolar Disorder and Treatment
- Genetic Neurodegenerative Diseases
- Neuroscience and Neuropharmacology Research
- Attention Deficit Hyperactivity Disorder
- Receptor Mechanisms and Signaling
- Psychotherapy Techniques and Applications
- Psychology Research and Bibliometrics
- Neuroscience and Neural Engineering
- Parkinson's Disease Mechanisms and Treatments
- Medical Imaging Techniques and Applications
- Psychosomatic Disorders and Their Treatments
Centro de Investigación Biomédica en Red de Salud Mental
2015-2024
Hospital de Sant Pau
2014-2024
Universitat Autònoma de Barcelona
2015-2024
Instituto de Salud Carlos III
2013-2024
Centro de Investigación Biomédica en Red
2013-2022
University of Washington
2016
Columbia University
2016
Harvard University
2016
Dalhousie University
2016
Massachusetts General Hospital
2016
Deep brain stimulation (DBS) is currently tested as an experimental therapy for patients with treatment-resistant depression (TRD). Here we report on the short- and long-term (1 yr) clinical outcomes tolerance of DBS in eight TRD patients. Electrodes were implanted bilaterally subgenual cingulate gyrus (SCG; Broadman areas 24-25), stimulated at 135 Hz (90-μs pulsewidth). Voltage active electrode contacts adjusted to maximize short-term responses. Clinical assessments included 17-item...
The aim of this study was to determine the efficacy and safety dialectical behavior therapy plus olanzapine compared with placebo in patients borderline personality disorder.Sixty disorder were included a 12-week, double-blind, placebo-controlled study. All received randomly assigned receive either or following 1-month baseline period.Seventy percent completed 4-month trial. Combined treatment showed an overall improvement most symptoms studied both groups. Olanzapine associated...
Background Although white-matter abnormalities have been reported in middle-aged patients with major depressive disorder (MDD), few data are available on treatment-resistant MDD and the influence of relevant variables related to clinical burden illness is far from being well established. Method The present study examined microstructure a sample 52 different stages (treatment-resistant/chronic MDD, n = 18; remitted-recurrent 15; first-episode 19) 17 healthy controls, using diffusion tensor...
<h3>Background:</h3> To date, antidepressant drugs show limited efficacy, leaving a large number of patients experiencing severe and persistent symptoms major depression. Previous open-label clinical trials have reported significant sustained improvements with deep brain stimulation (DBS) the subcallosal cingulate gyrus (SCG) in severe, chronic treatment-resistant depression (TRD). This study aimed to confirm efficacy measure impact discontinuation electrical stimulation. <h3>Methods:</h3>...
<h3>Background:</h3> Smaller hippocampal volumes in major depressive disorder (MDD) have been linked with earlier onset, previous recurrences and treatment refractoriness. The aim of our study was to investigate metabolite abnormalities the hippocampus associated past illness burden. <h3>Methods:</h3> Glutamate/glutamine (Glx), <i>N</i>-acetylaspartate (NAA) choline (Cho), potential markers glial/neuronal integrity membrane turnover, respectively, were measured adults depression healthy...
Findings of brain structural changes in major depressive disorder are still inconsistent, partly because some crucial clinical variables have not been taken into account.To investigate the effect on grey matter volumes.Voxel-based morphometry was used to compare 66 patients with depression at different illness stages (22 each first-episode, remitted-recurrent and treatment resistant/chronic depression) 32 healthy controls. Brain volumes were correlated variables.Voxel-based showed a...
BackgroundUp to 30% of patients with schizophrenia are resistant antipsychotic drug treatment, 60% such cases also failing respond clozapine. Deep brain stimulation (DBS) has been used in treatment other psychiatric disorders, but there is a lack trials schizophrenia, partly due uncertainties over where site the electrodes. This trial aimed examine effectiveness nucleus accumbens (NAcc) and subgenual anterior cingulate cortex (subgenual ACC) targeted DBS; primary outcome measure was PANSS...
Article AbstractObjective: The aim of this double-blind, placebo-controlled study was to evaluate the efficacy and tolerability ziprasidone in treatment adult patients with borderline personality disorder. Method: Sixty DSM-IV disorder were included from March 2004 April 2006 a 12-week, single-center, study. subjects randomly assigned or placebo 1:1 ratio following 2-week baseline period. Clinical Global Impressions scale for use (CGI-BPD) primary outcome measure, other scales self-reports...
Article AbstractObjective: Since depression entails not only dramatic personal disruption but also a huge amount of medical and socioeconomic burden, slowness antidepressant action difficulties to attain remission are entangled issues be solved. Given the controversial previous findings with enhancing strategies such as pindolol, we examined whether speed selective serotonin reuptake inhibitor (SSRI) can truly accelerated optimized pindolol dosage. Additionally, aimed at elucidating benefits...
In a controlled trial, the beta-adrenoceptor/5-hydroxytryptamine-1A (5-HT1A) receptor antagonist pindolol accelerated and enhanced antidepressant effect of fluoxetine. The median times to sustained response (> or = 50% reduction baseline severity maintained until endpoint) were 19 days for fluoxetine plus (N 55) 29 placebo 56) (p 0.01). rate at endpoint was 16% greater in patients treated with combination. plasma concentration remained stable between 3 (first blood sampling) 6 weeks. Mean...
The antidepressant efficacy of selective 5-HT reuptake inhibitors (SSRI) and other 5-HT-enhancing drugs is compromised by a negative feedback mechanism involving 5-HT(1A) autoreceptor activation the excess produced these in somatodendritic region neurones. receptor antagonists augment antidepressant-like effects rodents preventing this feedback, mixed β-adrenoceptor/5-HT(1A) antagonist pindolol improves clinical preferentially interacting with autoreceptors. However, it unclear whether not...